alexsl
- Raymond James upgraded Doximity (DOCS) to strong buy from outperform, saying that the digital platform for doctors with a “current risk/reward at 25x [free cash flow] looking too compelling to ignore.”
- The firm, however, lowered its target price to $65 from $75 (40% upside based on
